Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14033 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Bolong Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vagelos College of Physicians and Surgeons, Columbia University, New York City, New York, USA. Hauptthemen laut MEDLINE: Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines, Hematopoietic Stem Cell Transplantation, Tetanus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
Hematopoietic cell transplantation (HCT) recipients have reduced antibody titers to tetanus, diphtheria, and pertussis. Tdap is approved for revaccinating adult HCT recipients in the United States, whereas DTaP is not approved in this population. To our knowledge, no studies to date have compared responses to DTaP versus Tdap in adult HCT patients. We conducted a retrospective study comparing responses to DTaP versus Tdap vaccines in otherwise similar adult HCT patients in order to determine if one of these vaccines elicits superior antibody responses.
Methods
We evaluated 43 allogeneic and autologous transplant recipients as a combined cohort and as separate subsets for vaccine specific antibody titers and proportion of strong vaccine responders. Subset analysis focused on the autologous transplant recipients.
Results
Higher median antibody titers were found to all vaccine components among DTaP recipients (diphtheria p = .021, pertussis p = .020, tetanus p = .007). DTaP recipients also had more strong responders to diphtheria and pertussis (diphtheria p = .002, pertussis p = .006). Among the autologous HCT recipient subset, there were more strong responders to diphtheria ( p = .036).
Conclusions
Our data shows that post‐HCT vaccination with DTaP leads to higher antibody titers and more strong responders, which suggests that DTaP is more effective than Tdap in HCT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vagelos College of Physicians and Surgeons, Columbia University, New York City, New York, USA.
- Blood and Marrow Transplantation Program, Columbia University Irving Medical Center, New York City, New York, USA.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Xu, B., Gordillo, C. A., Delille, E. M., Malandrakis, S., Assal, A., Mapara, M. Y., & Reshef, R. (2023). Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients. European Journal of Haematology. https://doi.org/10.1111/ejh.14033
Vancouver
Xu B, Gordillo CA, Delille EM, Malandrakis S, Assal A, Mapara MY, et al. Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients. European Journal of Haematology. 2023. doi:10.1111/ejh.14033
BibTeX
@article{Xu2023,
author = {Xu, Bolong and Gordillo, Christian A and Delille, Elsa M and Malandrakis, Stephanie and Assal, Amer and Mapara, Markus Y and Reshef, Ran},
title = {Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14033}
}
EUVIMED